📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Genworth Financial, Inc., together with its subsidiaries, provides mortgage and long-term care insurance products in the United States.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding GNW

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Steve Cohen Point72 Asset Management	836.8K	$6.8M	0.01%	Mar 2026
Jim Simons Renaissance Technologies LLC	700.4K	$5.7M	0.01%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management uses language like 'solid second quarter', 'strong liquidity position', 'favorable judgment', and provides specific figures (net income $51M, AOI $68M, $31.6B NPV rate actions) without hedging.

Q3 2025

Confident Specific

Management used specific figures (e.g., $116M net income, $17M AOI, $134M from Enact, $254M cash, $31.8B MIRAP NPV) and repeatedly expressed confidence in strategic priorities, Enact's performance, and CareScout's growth. The tone is positive but realistic, acknowledging LTC pressures while emphasizing that GAAP fluctuations don't affect cash flows.

Q4 2025

Confident Specific

Management uses phrases like 'strong performance', 'continued to advance strategic priorities', 'pleased with the strong progress', and provides specific metrics (e.g., $146 million AOI from Enact, 3,255 matches, 925 matches in Q4, $25 million revenue guidance for 2026). The tone is precise and forward-looking.

Q1 2026 latest

Confident Specific

Management used specific numbers (e.g., $140M Enact AOI, $166M holding company cash, $34.5B cumulative MYRAP NPV) and repeatedly described performance as 'strong' and 'pleased', while acknowledging macro uncertainties and framing RBC decline as seasonal and manageable.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis remains largely unchanged after this call. Enact continues to deliver strong cash flows and capital returns, underpinning Genworth’s ability to fund share buybacks and CareScout growth. CareScout’s ramp is on track with clear milestones (matches, network coverage, revenue) and the closed block is being managed without new capital injections. The updated earnings presentation (excluding closed block) may help investors focus on the core growth businesses. The key risk remains the long-tail LTC closed block, but MYRAP execution and declining riskiest features provide comfort. Watch for the July AXA litigation appeal hearing and whether the RBC ratio stabilizes; also monitor CareScout’s progress toward 7,500 matches and $25M revenue to confirm scalability.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Genworth Q1 2026: $109M AOI excl. Closed Block; Enact $140M; 1,500 CareScout matches

Revenue & Profitability

For Q1 2026, Genworth reported net income of $47 million and adjusted operating income excluding the Closed Block of $109 million. Enact contributed $140 million, including a $39 million pre-tax reserve release. Enact's new insurance written was $13 billion, and earned premiums were $243 million. The holding company ended the quarter with $166 million in cash and liquid assets.

Outlook

Management sees strong demand from 70 million baby boomers aged 62-80 in 2026, driving long-term growth for CareScout. However, they note an uncertain macroeconomic backdrop with uneven consumer spending and the potential for higher inflation and interest rates. Genworth believes it is well-positioned to navigate these conditions, with Enact operating from a position of strength supported by disciplined underwriting and a strong capital position.

Growth Drivers

Key growth drivers include scaling CareScout: 1,500 matches in Q1 2026 (including first direct-to-consumer and senior living community matches), targeting 7,500 matches for the full year. CareScout aims to generate $25 million in service revenue in 2026, with $6 million achieved in Q1. New products such as a worksite Care Assurance product and hybrid LTC insurance are in development, while Enact continues to provide strong free cash flow, with expected capital returns of approximately $405 million to Genworth in 2026.

Balance Sheet & CapEx

Genworth plans to invest $50-55 million in CareScout Services in 2026 for technology, product expansion, and operational infrastructure. Several AI and agentic initiatives are underway with key partners focused on improving efficiency in claim management and customer service. For CareScout Insurance, no additional investments are expected in 2026 following the $85 million investment in 2025.

Margins

Not discussed in detail in this earnings call. Enact reported a low loss ratio of 15% due to favorable reserve releases, but management did not provide explicit margin trajectory or operating leverage guidance.

Key Risks

Risks flagged include the outcome of the AXA litigation (appeal hearing in July 2026); macroeconomic uncertainty with uneven consumer spending and potential higher inflation/interest rates; seasonal mortality in LTC and life insurance; and a decline in the estimated RBC ratio to 289%, still above the 250% target. The Closed Block’s self-sustainability depends on continued premium approvals and benefit reductions.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-06

Q2 2026 saw strong Enact results, $47M net income, and $112M adjusted operating income (ex-closed block). CareScout expanded its network and revenue, while the closed block posted a $110M loss due to adverse LTC experience. Share repurchases and capital returns remain key priorities.

Q1 2026 Q1 2026 2026-05-06

Q1 2026 saw strong Enact performance, $109M adjusted operating income (ex-Closed Block), and $66M in share repurchases. CareScout expanded its network and targets $25M in 2026 revenue, while the Closed Block remains self-sustaining with no capital contributions planned.

Q4 2025 Q4 2025 2026-02-24

Q4 2025 saw strong Enact performance offset by LTC losses, with net income of $2 million and $8 million Adjusted Operating Income. Strategic priorities advanced, including CareScout’s expansion and new product launch, while capital returns and investments remained robust.

Q3 2025 Q3 2025 2025-11-06

Q3 2025 saw $116M net income and $17M adjusted operating income, led by Enact's strong results and capital returns. CareScout expanded its network, completed the Seniorly acquisition, and launched a new LTC insurance product, while LTC legacy business remains in long-term run-off.

Q2 2025 Q2 2025 2025-07-31

Q2 2025 saw $51M net income and $68M adjusted operating income, with Enact driving results and expected to return $400M to shareholders this year. CareScout expanded its offerings and network, while a favorable AXA litigation outcome could yield $750M, pending appeals.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.